117 related articles for article (PubMed ID: 8828469)
1. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia.
Evans GL; Bryant HU; Magee DE; Turner RT
Endocrinology; 1996 Oct; 137(10):4139-44. PubMed ID: 8828469
[TBL] [Abstract][Full Text] [Related]
2. Differential responses of estrogen target tissues in rats including bone to clomiphene, enclomiphene, and zuclomiphene.
Turner RT; Evans GL; Sluka JP; Adrian MD; Bryant HU; Turner CH; Sato M
Endocrinology; 1998 Sep; 139(9):3712-20. PubMed ID: 9724022
[TBL] [Abstract][Full Text] [Related]
3. The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
Evans G; Bryant HU; Magee D; Sato M; Turner RT
Endocrinology; 1994 May; 134(5):2283-8. PubMed ID: 8156931
[TBL] [Abstract][Full Text] [Related]
4. Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats.
Jimenez MA; Magee DE; Bryant HU; Turner RT
Endocrinology; 1997 May; 138(5):1794-800. PubMed ID: 9112370
[TBL] [Abstract][Full Text] [Related]
5. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
[TBL] [Abstract][Full Text] [Related]
6. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
Sato M; Turner CH; Wang T; Adrian MD; Rowley E; Bryant HU
J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314
[TBL] [Abstract][Full Text] [Related]
7. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
[TBL] [Abstract][Full Text] [Related]
8. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.
Sato M; Bryant HU; Iversen P; Helterbrand J; Smietana F; Bemis K; Higgs R; Turner CH; Owan I; Takano Y; Burr DB
J Pharmacol Exp Ther; 1996 Oct; 279(1):298-305. PubMed ID: 8859007
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats.
Wronski TJ; Yen CF; Qi H; Dann LM
Endocrinology; 1993 Feb; 132(2):823-31. PubMed ID: 8425497
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene preserves bone strength and bone mass in ovariectomized rats.
Turner CH; Sato M; Bryant HU
Endocrinology; 1994 Nov; 135(5):2001-5. PubMed ID: 7956922
[TBL] [Abstract][Full Text] [Related]
11. Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia.
Sibonga JD; Dobnig H; Harden RM; Turner RT
Endocrinology; 1998 Sep; 139(9):3736-42. PubMed ID: 9724025
[TBL] [Abstract][Full Text] [Related]
12. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
[TBL] [Abstract][Full Text] [Related]
14. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats.
Sato M; McClintock C; Kim J; Turner CH; Bryant HU; Magee D; Slemenda CW
J Bone Miner Res; 1994 May; 9(5):715-24. PubMed ID: 8053401
[TBL] [Abstract][Full Text] [Related]
15. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
Nuttall ME; Bradbeer JN; Stroup GB; Nadeau DP; Hoffman SJ; Zhao H; Rehm S; Gowen M
Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
Sato M; Rippy MK; Bryant HU
FASEB J; 1996 Jun; 10(8):905-12. PubMed ID: 8666168
[TBL] [Abstract][Full Text] [Related]
17. Evidence that ibuprofen antagonizes selective actions of estrogen and tamoxifen on rat bone.
Sibonga JD; Bell NH; Turner RT
J Bone Miner Res; 1998 May; 13(5):863-70. PubMed ID: 9610751
[TBL] [Abstract][Full Text] [Related]
18. Ovarian status influences the skeletal effects of tamoxifen in adult rats.
Sibonga JD; Evans GL; Hauck ER; Bell NH; Turner RT
Breast Cancer Res Treat; 1996; 41(1):71-9. PubMed ID: 8932878
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene analog (LY117018 HCL) ameliorates cyclosporin A-induced osteopenia in oophorectomized rats.
Bowman AR; Sass DA; Marshall I; Ma YF; Liang H; Jee WS; Epstein S
J Bone Miner Res; 1996 Aug; 11(8):1191-8. PubMed ID: 8854256
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
